{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-009573","form_type":"8-K","ticker":"CPRX","cik":"0001369568","company_name":"CATALYST PHARMACEUTICALS, INC.","filed_at":"2025-01-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.449353+00:00","generated_at":"2026-05-27T21:59:30.591083+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Catalyst sub-licensee DyDo launches FIRDAPSE in Japan for LEMS","bullets":["DyDo Pharma launched FIRDAPSE (amifampridine) 10 mg tablets in Japan for Lambert-Eaton myasthenic syndrome (LEMS).","FIRDAPSE is the only U.S. FDA-approved therapy for LEMS in adults and pediatric patients 6 years and older.","Previously approved in U.S., Europe, and Canada; Japan launch expands geographic footprint.","Catalyst CEO Richard Daly cited commitment to health equity and increasing patient access worldwide."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-009573","json":"https://secwatch.observer/filing/0001193125-25-009573.json","markdown":"https://secwatch.observer/filing/0001193125-25-009573.md","text":"https://secwatch.observer/filing/0001193125-25-009573.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1369568/000119312525009573/0001193125-25-009573-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1369568/000119312525009573/d848918d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T21:59:30.591083+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}